← Back to Clinical Trials
Recruiting NCT05359796

NCT05359796 Clinical Characteristics of People With Long-term Type 1 Diabetes

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05359796
Status Recruiting
Phase
Sponsor Second Xiangya Hospital of Central South University
Condition Type 1 Diabetes
Study Type OBSERVATIONAL
Enrollment 400 participants
Start Date 2022-05-01
Primary Completion 2025-12-31

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Chronic hyperglycemiaResidual islet functionGenetic variation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 400 participants in total. It began in 2022-05-01 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Type 1 diabetes (T1D) is characterized by absolute insulin deficiency. Although the discovery and application of exogenous insulin has prolonged the lifespan of T1D patients, the chronic diabetic complications caused by long-term poor glycemic control will still reduce patients' quality of life and the overall life expectancy. According to the studies focused on long-term T1D, part of the patients with long disease duration showed resistance to microvascular complications, and several protective factors have been identified. The prevalence of T1D in China is extremely low compared to that in the western world, and little is known about the characteristics of patients with long-term T1D in China. Therefore, this study is designed to collect variable clinical and laboratory features of patients with long-term T1D, explore the risk and protective factors for the development of microvascular complications, and provide reference for the prediction and prevention of these complications.

Eligibility Criteria

Inclusion Criteria: * Individuals diagnosed with type 1 diabetes(T1D) according to the 1999 World Health Organization report * Insulin dependence from disease onset * with T1D duration of ≥10 years * able to understand the procedures and methods of this study, voluntarily participate in the study, and agree to sign the informed consent form Exclusion Criteria: * patients with type 2 diabetes, gestational diabetes, or specific types of diabetes * patients with mental disability or have any other condition or disease that may hamper compliance with the protocol

Contact & Investigator

Central Contact

Xia Li, MD/PHD

✉ lixia2014@vip.163.com

📞 +86 17373199692

Principal Investigator

Xia Li, MD/PHD

PRINCIPAL INVESTIGATOR

Central South University

Frequently Asked Questions

Who can join the NCT05359796 clinical trial?

This trial is open to participants of all sexes, studying Type 1 Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05359796 currently recruiting?

Yes, NCT05359796 is actively recruiting participants. Contact the research team at lixia2014@vip.163.com for enrollment information.

Where is the NCT05359796 trial being conducted?

This trial is being conducted at Changsha, China.

Who is sponsoring the NCT05359796 clinical trial?

NCT05359796 is sponsored by Second Xiangya Hospital of Central South University. The principal investigator is Xia Li, MD/PHD at Central South University. The trial plans to enroll 400 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology